Expanding North American Demand Will Unlock New Health Trends

Key Takeaways

• Expansion in direct sales and mainstream retail channels supports sustained growth as preventative health trends and demand for natural, clinically-proven products intensify globally.
  
• Increased investment in innovation, marketing, and clinical research is expected to drive margin expansion and diversification despite short-term earnings pressure.
  
• High operating expenses, weak cash flow, and dependence on pediatric products pose profitability and diversification risks, potentially undermining long-term growth and financial flexibility.

Catalysts

A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.

• Strong growth in the Adult Health segment (23% net of currency effects), increased uptake in North America, and expanding presence in major U.S. retail chains (CVS, Target, Walmart) indicate untapped revenue potential as global health awareness and preventative care become more mainstream, likely driving sustained top-line growth.
  
• BioGaia's strategic shift to direct sales in new and existing markets (e.g., Netherlands, France, Australia, U.S.) leverages rising consumer demand for natural and clinically-proven solutions, paving the way for improved operating leverage and long-term margin expansion as direct business now represents 36% of sales and continues to grow.
  
• Accelerated investment in marketing and clinical research-though temporarily pressuring EBIT and net margins-supports competitive positioning as consumers increasingly prioritize natural and science-backed probiotics, suggesting current margin compression is transitory and margins will likely expand as scale is achieved and investments normalize.
  
• Launch of BioGaia New Sciences and entry into new product categories like skin microbiome signal further diversification and capture of emerging market needs, driven by global demographic shifts (aging populations, increased disposable income), with the potential to drive both revenue growth and improved average selling prices over time.
  
• Ongoing product innovation and expansion of condition-specific probiotics (e.g., strong growth in oral health with Prodentis, broader international rollouts) positions BioGaia to benefit from heightened focus on differentiated, clinically-validated offerings, supporting premium pricing and future earnings growth.

BioGaia Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming BioGaia's revenue will grow by 11.6% annually over the next 3 years.
• Analysts assume that profit margins will increase from 19.9% today to 28.6% in 3 years time.
• Analysts expect earnings to reach SEK 571.4 million (and earnings per share of SEK 4.92) by about August 2028, up from SEK 286.6 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 28.6x on those 2028 earnings, down from 33.3x today. This future PE is greater than the current PE for the GB Biotechs industry at 27.4x.
• Analysts expect the number of shares outstanding to grow by 0.18% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 4.92%, as per the Simply Wall St company report.

BioGaia Future Earnings Per Share Growth

Risks

• Operating expenses grew by 25% year-over-year, primarily driven by aggressive marketing and expansion initiatives in key markets like the U.S., France, and the Netherlands; if this spending does not yield increased revenue or rapid payback, it could pressure net margins and reduce earnings over the long term.
  
• EBIT dropped by 20% and EBIT margin declined to 27% (from 35% last year); persistently lower margins, coupled with high ongoing investments in direct sales and new markets, may erode long-term profitability if gross margin improvements in adult health are not sustained.
  
• Cash balance has dropped to SEK 622 million from SEK 1 billion a year ago, with cash flow from operating activities down 35% versus last year; if cash outflows continue to outpace inflows due to rising OpEx and flat sales growth, future capacity to invest in R&D, innovation, or acquisitions could be limited, impacting revenue and earnings resilience.
  
• Pediatric segment continues to account for 75-77% of sales, showing product category concentration; a lack of strong diversification or over-reliance on a limited portfolio (especially core products like Protectis) makes BioGaia vulnerable to changes in demand, competition, or scientific scrutiny in pediatrics, threatening both revenue growth and market share.
  
• Negative currency effects, combined with modest top-line growth in key EMEA markets (declines in Turkey, France, Germany and stagnant or declining performance in EMEA overall), highlight ongoing geographic and FX risk; long-term underperformance in major regions could stall revenue diversification efforts and put additional downward pressure on net margins and earnings.

Valuation

• The analysts have a consensus price target of SEK140.0 for BioGaia based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be SEK2.0 billion, earnings will come to SEK571.4 million, and it would be trading on a PE ratio of 28.6x, assuming you use a discount rate of 4.9%.
• Given the current share price of SEK94.35, the analyst price target of SEK140.0 is 32.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.